
Corcept Therapeutics (CORT): Lifyorli Launch Drives Growth
Corcept is evolving from a single-product endocrinology story into a two-franchise biopharma company, with Lifyorli adding a new growth engine. The stock looks fairly valued after strong Q2 revenue growth, but execution risk and a young launch keep the rating at Hold.
